TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 132901
Drug: Topical tetracycline
Normalized name: TETRACYCLINE HYDROCHLORIDE 30 mg in 1 mL TOPICAL SPRAY [Tetracyte Topical Tetracycline Hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tetracycline hydrochloride and orally administered lactose capsules
Study: 132901
Drug: Orally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered tetracycline hydrochloride and topically applied placebo liquid
Study: 132901
Drug: Topically applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topically applied placebo liquid and orally administered tetracycline hydrochloride
Study: 27908689
Drug: PCSK9 genetic
Normalized name: Burosumab (genetical recombination)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCSK9 genetic variants (rs11583680, rs11591147, rs2479409, rs11206510) scaled to 1 mmol/L lower LDL cholesterol
Study: 25181297
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for regular past tense, one-hour play-based sessions, once weekly for eight weeks
Study: 25181297
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for regular past tense
Study: 17026815
Drug: Gemcitabine 1250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1250 mg/m² on days 1 and 8 plus carboplatin AUC 5 on day 1
Study: 11126695
Drug: Randomised treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomised treatment allocation
Study: 8989012
Drug: Fentanyl 1.5
Normalized name: fentanyl 1.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 1.5 micrograms/kg intravenous (i.v.) administration
Study: 8452180
Drug: Fleroxacin 400
Normalized name: fleroxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fleroxacin 400 mg daily for 7 days
Study: 8452180
Drug: Fleroxacin 400
Normalized name: fleroxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fleroxacin 400 mg daily for 14 days
Study: 8452180
Drug: Chloramphenicol 50
Normalized name: chloramphenicol 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloramphenicol 50 mg/kg per day for 14 days
Study: 3088648
Drug: Naloxone (0.0625,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (0.0625, 0.25, 1.0, or 4.0 mg/kg)
Study: 24619608
Drug: Brace treatment
Normalized name: Brace Relief
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brace treatment (Br group)
Study: 16652130
Drug: bioactive supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: bioactive supplement (n=57)
Study: 11834192
Drug: Olanzapine (OLZ)
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olanzapine (OLZ) 2.5 or 5.0 mg daily
Study: 314777
Drug: Low-dosage ampicillin
Normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-dosage ampicillin (150 mg/kg per day)
Study: 28390417
Drug: Standard cognitive‐behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard cognitive‐behavioral smoking cessation treatment
Study: 28390417
Drug: Standard cognitive‐behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard cognitive‐behavioral smoking cessation treatment plus behavioral activation
Study: 16132779
Drug: Erythropoietin (EPO)
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin (EPO) therapy at a dose of 2000 U subcutaneously thrice weekly
Study: 2006566
Drug: Lovastatin 40
Normalized name: lovastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin 40 mg daily for 30 days
Study: 6754505
Drug: Gentamicin otic
Normalized name: gentamicin Otic Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin otic solution (0.3%)
Study: 6754505
Drug: Colistin-neomycin-hydrocortisone otic
Normalized name: colistin / hydrocortisone / neomycin / thonzonium Otic Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colistin-neomycin-hydrocortisone otic suspension (colistin 0.3%, neomycin 0.33%, hydrocortisone 1.0%)
Study: 28728599
Drug: CinnoRA® (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: CinnoRA® (40 mg subcutaneous injections every other week)
Study: 28728599
Drug: Humira® (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Humira® (40 mg subcutaneous injections every other week)
Study: 12176948
Drug: Simvastatin 80
Normalized name: simvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 80 mg monotherapy for 2 years
Study: 7857504
Drug: 900 mg
Normalized name: diosmin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg of hypericum per day combined with bright light therapy (3000 lux)
Study: 7857504
Drug: 900 mg
Normalized name: diosmin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg of hypericum per day combined with dim light therapy (< 300 lux)
Study: 8899078
Drug: Sucrose polyester
Normalized name: polyester-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucrose polyester (50 g as a single drink)
Study: 6679229
Drug: Verapamil (IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (IV administration, bolus of 0.075 mg/kg up to 5 mg)
Study: 6679229
Drug: Verapamil (IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (IV administration)
Study: 19720927
Drug: Bevacizumab 10
Normalized name: bevacizumab 100 MG in 4 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab 10 mg/kg alone
Study: 19720927
Drug: Bevacizumab plus
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab plus irinotecan 340 mg/m2 or 125 mg/m2
Study: 9000658
Drug: MMF 2
Normalized name: MMF
DrugBank: Monomethyl fumarate (DB14219)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMF 2 g and MMF 3 g
Study: 24152889
Drug: Ferrous bisglycinate
Normalized name: FERROUS BISGLYCINATE
DrugBank: Ferrous bisglycinate (DB11210)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous bisglycinate 25 mg iron/day
Study: 24152889
Drug: Ferrous sulfate
Normalized name: Ferrous Sulfate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous sulfate 50 mg iron/day
Study: 15998425
Drug: Non-interferon-based therapy
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-interferon-based therapy (N-IFN-BT) - ribavirin (600-800 mg) + amantadine (200 mg) + ursodeoxycholic acid (UDCA) (500 mg) for 24 weeks
Study: 15998425
Drug: Non-interferon-based therapy
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-interferon-based therapy (N-IFN-BT)
Study: 15998425
Drug: Silymarin therapy
Normalized name: silymarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silymarin therapy - 450 mg/day for 24 weeks
Study: 8886216
Drug: Naprelan 1000
Normalized name: Naprelan
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naprelan 1000 mg
Study: 2268862
Drug: Naproxen 500
Normalized name: naproxen 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 500 mg
Study: 19937046
Drug: Codeine 30
Normalized name: codeine 30 MG
DrugBank: Codeine (DB00318)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Codeine 30 mg
Study: 22775078
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept 4 mg
Study: 22775078
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept 0.15 mg
Study: 20151792
Drug: Estradiol (E2)
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol (E2) 1 mg/day + norethisterone acetate (NETA) 0.5 mg/day for 2 months, followed by placebo for 4 months
Study: 12697871
Drug: Three 72-hour
Normalized name: THREE-LOBE SAGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three 72-hour infusions of carmustine (BiCNU) and cisplatin followed by radiation therapy
Study: 12697871
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy with standard adjuvant BiCNU
Study: 7902369
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of naltrexone
Study: 2994500
Drug: Schedule A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schedule A (once daily by rapid infusion)
Study: 2994500
Drug: Schedule B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schedule B (continuous 24 hr infusion)
Study: 2994500
Drug: Schedule C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schedule C (divided doses every eight hours by rapid infusion)
Study: 23364033
Drug: Passive upper
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Passive upper arm exercise for 30 minutes per session, twice a day for 2 weeks
Study: 15940046
Drug: Low-dose dopamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dopamine (LDD) infusion over the second 3-hr period
Study: 15940046
Drug: Low-dose dopamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dopamine (LDD) infusion over both the first and third 3-hr periods
Study: 10412886
Drug: 1.5 g
Normalized name: Vaporizer Vicks 1.5 gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g of paracetamol orally
Study: 7002479
Drug: Glucosamine sulphate
Normalized name: Glucosamine Sulfate 750 MG Oral Capsule [GLUCOSAMINE SULPHATE]
DrugBank: Glucosamine (DB01296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucosamine sulphate (250 mg, 3 times daily for 6 to 8 weeks)
Study: 7002479
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 capsules, 3 times daily for 6 to 8 weeks)
Study: 26224692
Drug: Culture-directed antibiotic
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culture-directed antibiotic therapy for 2 weeks
Study: 23650968
Drug: Intranasal fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal fentanyl spray (INFS)
Study: 14611914
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy after complete resection
Study: 14611914
Drug: Postoperative treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative treatments (chemotherapy, radiotherapy or both)
Study: 1636624
Drug: Glyburide with
Normalized name: Glyburide
DrugBank: Glyburide (DB01016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glyburide with fish oil (8 g/d)
Study: 2936285
Drug: 0.10 mg
Normalized name: povidone-iodine 0.10 mg in 1 mL TOPICAL SOLUTION [Povidone Iodine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.10 mg . kg‐1 atracurium dibesylate
Study: 2936285
Drug: 0.15 mg
Normalized name: iodine 0.15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 mg . kg‐1 atracurium dibesylate
Study: 29557754
Drug: AC+AN+HL ointment
Normalized name: Aldex AN
DrugBank: Doxylamine (DB00366)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AC+AN+HL ointment mixture (Group A, N=21)
Study: 29557754
Drug: AC ointment
Normalized name: Halonate PAC Ointment Pack
DrugBank: Actinium (DB12860)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AC ointment alone (Group B, N=20)
Study: 15960427
Drug: Control NT
Normalized name: NT-219
DrugBank: NT-219 (DB17490)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control NT - no immunostimulating treatment.
Study: 10515817
Drug: Pneumococcal conjugate
Normalized name: pneumococcal conjugate PCV 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pneumococcal conjugate vaccines (3 experimental vaccines containing 6B and 19F)
Study: 10515817
Drug: Pneumococcal conjugate
Normalized name: pneumococcal conjugate PCV 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pneumococcal conjugate vaccines (2 experimental vaccines)
Study: 10515817
Drug: Pneumococcal conjugate
Normalized name: pneumococcal conjugate PCV 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pneumococcal conjugate vaccines (1 experimental vaccine)
Study: 26277887
Drug: pioglitazone 15
Normalized name: pioglitazone 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: pioglitazone 15 mg once daily
Study: 26277887
Drug: alogliptin 25
Normalized name: alogliptin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: alogliptin 25 mg once daily (control)
Study: 21775563
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (2.7 g long-chain n-3 fatty acids daily during the third trimester)
Study: 19957549
Drug: Goserelin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goserelin with 1/2 piece of estradiol patch weekly and 6 mg oral medroxyprogesterone acetate daily for 12 weeks (Group B)
Study: 19957549
Drug: Goserelin 3.6
Normalized name: goserelin 3.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goserelin 3.6 mg once every 4 weeks for 12 weeks (Group A)
Study: 15386934
Drug: G‐Hesperidin at
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐Hesperidin at 100 or 500 mg/d for 6 weeks
Study: 11496020
Drug: Fluoxetine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (6 weeks open-label treatment followed by 6 weeks double-blind treatment)
Study: 11496020
Drug: Placebo (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (6 weeks double-blind treatment)
Study: 2205182
Drug: 0.5% topical
Normalized name: Carac 0.5% Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% topical apraclonidine hydrochloride
Study: 2205182
Drug: 0.25% topical
Normalized name: Remyda, 0.25% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25% topical apraclonidine hydrochloride
Study: 71971
Drug: Flurbiprofen 150
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flurbiprofen 150 mg twice daily (morning and evening) plus placebo at mid-day
Study: 71971
Drug: Flurbiprofen 100
Normalized name: flurbiprofen 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen 100 mg three times daily
Study: 71971
Drug: Flurbiprofen 150
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flurbiprofen 150 mg twice daily
Study: 27712924
Drug: Testosterone administration
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone administration for 48h
Study: 7645530
Drug: Propranolol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (40 mg 3 times daily)
Study: 7710444
Drug: 0.5-20 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5-20 mg intravenous pancopride
Study: 7710444
Drug: 5-40 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-40 mg oral solution of pancopride
Study: 7710444
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg intravenous infusion, oral tablet and oral solution
Study: 7008978
Drug: Topical benzydamine
Normalized name: benzydamine Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical benzydamine (10/00)
Study: 23327032
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg hyperbaric bupivacaine 0.5%
Study: 23327032
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg hyperbaric bupivacaine 0.5%
Study: 10442363
Drug: Adjuvant UFT
Normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant UFT (400 mg/day for 12 months)
Study: 8578802
Drug: Diphtheria/Tetanus (DT)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphtheria/Tetanus (DT) vaccine
Study: 2190540
Drug: Oral low
Normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral low dose cyclophosphamide
Study: 19201289
Drug: Oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo treatment
Study: 2190540
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose cyclophosphamide
Study: 30640148
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of BCTs (COMBO)
Study: 23877691
Drug: GS-5885 1
Normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: GS-5885 1 mg once daily
Study: 23877691
Drug: GS-5885 ≥3
Approvals — FDA: no, EMA: no, PMDA: no
Description: GS-5885 ≥3 mg once daily
Study: 23877691
Drug: GS-5885 30
Normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: GS-5885 30 mg and 90 mg once daily
Study: 20309694
Drug: Intravenous cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cyclophosphamide (CyP) only
Study: 16464962
Drug: Combined use
Normalized name: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined use of paracetamol and ibuprofen
Study: 12957421
Drug: Glucose-insulin-potassium (GIK)
Normalized name: glucose / potassium chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose-insulin-potassium (GIK) infusion for 8 to 12 hours
Study: 8891888
Drug: Isocaloric, reduced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isocaloric, reduced fat (< 30%) low‐cholesterol diet with pravastatin (40 mg/day)
Study: 28816281
Drug: Intravenous flurbiprofen
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous flurbiprofen axetil (1 mg/kg) 1 hour before the procedure
Study: 28816281
Drug: Intrarectal 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrarectal 5% lidocaine gel (60 mg) 5 minutes before the procedure
Study: 28816281
Drug: Intrarectal 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrarectal 5% lidocaine gel (60 mg) 5 minutes before the procedure and intravenous flurbiprofen axetil (1 mg/kg) 1 hour before the procedure
Study: 23065047
Drug: Herbal medicine
Normalized name: Herbal medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal medicine
Study: 29883936
Drug: Psychotropic medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychotropic medications
Study: 23752495
Drug: Energy-maintenance diet
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Energy-maintenance diet (27 g NSP and 5 g RS)
Study: 16126804
Drug: Intramuscular gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular gentamicin 5 mg/kg/day once-daily (OD)
Study: 16126804
Drug: Intramuscular gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular gentamicin 5 mg/kg/day thrice-daily (TD)
Study: 15071015
Drug: Structured treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured treatment interruptions (STIs)
Study: 15071015
Drug: No structured
Approvals — FDA: no, EMA: no, PMDA: no
Description: No structured treatment interruptions (Control)
Study: 9564977
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (BDP) 336 microg/day by metered dose inhaler (MDI)
Study: 8044782
Drug: Irinotecan (CPT‐11)
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Irinotecan (CPT‐11) administered at dose levels ranging from 50 to 145 mg/m2 (30‐90 min i.v. infusion)
Study: 3051962
Drug: Golytely-RSS plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Golytely-RSS plus oral bisacodyl
Study: 24788581
Drug: Multidimensional Stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidimensional Stimulation group Therapy (MST)
Study: 17062365
Drug: FGF 2
Normalized name: FGF 2
DrugBank: Basic Fibroblast Growth Factor (DB14131)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FGF 2 L/min with 1% isoflurane
Study: 17062365
Drug: FGF 3
Normalized name: Fibroblast Growth Factor 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: FGF 3 L/min with 2% isoflurane
Study: 373792
Drug: Loestrin-20 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loestrin-20 (20 microgram ethinyl oestradiol and 1 mg norethisterone acetate)
Study: 6365466
Drug: Piretanide 6
Normalized name: piretanide 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piretanide 6 mg per day
Study: 6365466
Drug: Piretanide 12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piretanide 12 mg per day
Study: 29158143
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg Tobrate™
Study: 24419562
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea (700 ml/day for 14 days)
Study: 22748970
Drug: Rabeprazole granules
Normalized name: rabeprazole Granule Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole granules mixed with soft food or infant formula (10 mg)
Study: 22748970
Drug: Rabeprazole suspension
DrugBank: Rabeprazole (DB01129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rabeprazole suspension with inactive vehicle granules (reference)
Study: 22748970
Drug: All treatment-emergent
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatment-emergent adverse events (TEAEs)
Study: 17494097
Drug: Transdermal testosterone
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal testosterone (T) gel (100 mg/d) plus depomedroxyprogesterone acetate (300 mg intramuscularly every 12 weeks) with GnRH antagonist acyline (300 microg/kg subcutaneously every 2 weeks for 12 weeks)
Study: 9918907
Drug: Losartan 25
Normalized name: LOSARTAN 25MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 25 mg orally once daily for 1 week
Study: 7307428
Drug: Morphine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (10 or 20 mg/70 kg)
Study: 7213520
Drug: Heroin (3,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heroin (3, 6, 12 mg/70 kg)
Study: 30885157
Drug: Co-administration of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administration of ivermectin and albendazole
Study: 30885157
Drug: Albendazole monotherapy
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albendazole monotherapy (control)
Study: 19309197
Drug: Continuation-phase cognitive
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuation-phase cognitive therapy (C-CT)
Study: 20306476
Drug: Oral calcitriol
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral calcitriol 0.25 mcg twice daily for 1 week, followed by oral calcitriol 0.50 mcg twice daily for 1 week
Study: 2099194
Drug: Genivir (DIP-253)
Normalized name: West Dip
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genivir (DIP-253) 1% cream